Broadcast Date: 
  • Time: 

Novel or next-generation biologics such as bispecific antibodies (bsAbs) and fusion proteins present unique development and manufacturing process challenges due to complex formats, suboptimal stability, product aggregation, or low productivity. These issues impact product quality and consistency, as well as the ability to develop efficient and scalable processes. Successfully addressing these challenges while reducing the cost of goods (COGs) requires the strategic utilization of advanced technologies, appropriate analytical methods, extensive experience, as well as adopting a proactive approach to de-risk the biotherapeutics development.

In this GEN webinar, our speakers will present WuXi Biologics’ suite of advanced solutions for overcoming obstacles associated with the development and manufacturing of complex biologics.

In this webinar you’ll learn:

• The evolving landscape of new modalities and the holistic challenges in CMC development for complex biotherapeutics

• Technical strategies to address specific challenges in bispecific antibody (bsAb) development

• Solutions to achieve efficient and successful fusion protein development in mammalian protein expression systems

• Case studies and experience sharing on strategies to reduce COGs for complex biologic modalities

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Yifeng Li,
Xiaoyue Chenn, PhD
Head of Cell Line Development
WuXi Biologics
Xiaoyue Chenn
Yifeng Li, PhD
Head of Downstream Process Development
WuXi Biologics


Previous articleNirrin Launches Atlas for At-Line Analysis at the Point of Sampling
Next articleRespiratory Bacteria “Talk” Immune System into Tolerating Infection